Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W McCarthy

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Jane A O'Halloran, Eyal Kedar, Kevin J Anstrom, et al.
JAMA|August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical TrialNicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2022
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Emily R Ko, Kevin J Anstrom, Reynold A Panettieri, et al.
JAMA|July 10, 2023
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical TrialJane A O'Halloran, Emily R Ko, Kevin J Anstrom, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|September 29, 2022
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Jane A O'Halloran, Eyal Kedar, Kevin J Anstrom, et al.
JAMA|August 13, 2025
Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical TrialNicholas A Turner, Toshimitsu Hamasaki, Sarah B Doernberg, et al.
Medrxiv : the Preprint Server for Health Sciences|October 7, 2022
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19Emily R Ko, Kevin J Anstrom, Reynold A Panettieri, et al.
JAMA|July 10, 2023
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical TrialJane A O'Halloran, Emily R Ko, Kevin J Anstrom, et al.
Pageof 8